Ryan F. Quarles: “I do think that certainly, the way that we have implemented the Volcker Rule... it has been excessively burdensome.”

It is not our intention. Indeed, it is the opposite of our intention, to affect the total loss-absorbing capacity of the largest firms.

Markets are always ahead of the regulators. Frankly, that is how it should be.

The FDA needs to provide regulatory pathways for products containing CBD. The FDA needs to act now.

That is probably the highest priority item that we have, discussing ways to ensure that our systems are resilient.